# Study of Efficacy and Safety of MAS825 in Patients With COVID-19

> **NCT04382651** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 140 (actual)

## Conditions studied

- COVID-19 Pneumonia, Impaired Respiratory Function

## Interventions

- **DRUG:** MAS825
- **OTHER:** Placebo
- **DRUG:** Standard of Care (SoC)

## Key facts

- **NCT ID:** NCT04382651
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-11
- **Primary completion:** 2021-01-06
- **Final completion:** 2021-04-21
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2022-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04382651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04382651, "Study of Efficacy and Safety of MAS825 in Patients With COVID-19". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT04382651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*